Introduction {#sec1}
============

The fibroblast growth factor (FGF) family of ligands and receptors execute a wide range of biological functions in development, tissue repair, angiogenesis and cellular homeostasis.^[@ref1]−[@ref3]^ Dysregulation of the FGF signaling axis by a diversity of mechanisms is a frequent feature of a range of different tumor cell types^[@ref4],[@ref5]^ and, as a result, the FGF pathway is the target for the development of small molecule kinase inhibitors and other forms of therapeutic intervention.([@ref2]) However, to better inform the development of therapeutic interventions in the FGF pathway, and analyze their molecular actions, a complete understanding of the architecture of the downstream processes activated by FGF signaling is required. In this study we apply a differential phosphoproteomics approach to the identification of phosphorylation events mediated during activation of FGFR signaling.

Current understanding of the FGF signaling pathway holds that, following receptor dimerization by ligand engagement, activation of the intrinsic receptor tyrosine kinase leads to phosphorylation of key tyrosine residues on the receptor itself and the receptor-associated docking protein FRS2.^[@ref6],[@ref7]^ These phosphorylation events provide the basis for recruitment of effector proteins bearing sequence-specific phosphotyrosine recognition domains, which leads to further recruitment of downstream effectors and activation of intracellular signaling processes. The most prominent pathways associated with this mechanism are activation of the Ras/Raf/ERK pathway via recruitment of the adaptor protein Grb2 and the RasGEF SOS^[@ref8],[@ref9]^ activation of the PI3 kinase/PDK/Akt pathway via recruitment of the adaptor protein Gab1^[@ref10],[@ref11]^ and activation of phospholipase C via direct recruitment, via its SH2 domain, to the receptor.([@ref12]) Recent studies have provided further elaboration of this core pathway. A targeted mass spectrometric analysis of proteins that interact with activated FGFRs([@ref13]) identified a plethora of proteins associated with intracellular vesicular trafficking. One such partner, the small GTPase Rab5, has been shown to be crucial for sustaining propagation of the Ras/Raf/ERK, but not the PI3K/PDK/Akt signal. Additionally the non receptor tyrosine kinase c-Src has been shown to be rapidly recruited to the activated receptor complex, and Src kinase activity is required for both the initiation of FGF signaling and termination of the Ras/Raf/ERK pathway but not the PI3K/PDK/Akt pathway.([@ref14]) These findings point to the existence of further, as yet uncharacterized, mediators of FGFR signaling that are targets for Src kinase-mediated phosphorylation and functionally implicated in FGFR trafficking of activated FGFRs.

During recent years, phosphoproteomic studies have successfully identified large numbers of phosphorylation sites.^[@ref15]−[@ref17]^ This success is due in large part to efficient enrichment techniques for phosphopeptides and improvements in mass spectrometric instrumentation.([@ref18]) To obtain more biologically informative results from these types of studies, some form of quantitation can be applied.([@ref19]) In particular, stable isotope labeling with amino acids in cell culture (SILAC) is capable of quantifying even relatively subtle changes in protein levels.^[@ref20],[@ref21]^ Recently, software has been designed specifically to both improve SILAC data analysis and to cope with the large data sets generated from these experiments.([@ref22])

In this study, we set out to identify further direct and indirect phosphorylation events on protein targets for Src family kinases (SFKs) downstream of FGFR using ultrahigh resolution mass spectrometry techniques.([@ref23]) Previous proteomic studies of the FGFR tyrosine kinase pathway have relied on overexpression of FGFR.^[@ref13],[@ref24],[@ref25]^ Rather than overexpress FGFR, we chose to combine FGF stimulation with pervanadate treatment to maximize the levels of tyrosine phosphorylated substrates. A similar approach using pervanadate treatment has been used in previous phosphoproteomics studies.^[@ref21],[@ref26]−[@ref28]^ We applied SILAC combined with chemical inhibition of SFK activity to search for phosphorylation events that are dependent on SFK activity in FGF stimulated cells. SILAC has previously been used to study Src-substrates in cells overexpressing Src,([@ref28]) in Src-transformed cells,([@ref29]) and using chemical inhibition of SFK activity downstream of the PDGF receptor.([@ref30]) However, much of the data obtained identifies proteins as tyrosine phosphorylated without localizing the exact site of phosphorylation, and information regarding regulation on specific tyrosine phosphorylation sites of Src substrates is lacking.

Here, we identify 80 SFK-dependent phosphorylation events on 40 target proteins, including known Src substrates, downstream kinases and adaptor proteins. To illustrate further application of SILAC techniques to characterization of specific SFK-mediated phosphorylation events, we used a more targeted approach to carry out high coverage phosphopeptide mapping of one Src substrate protein, the multifunctional adaptor Dok1, and to identify SFK-dependent Dok1 binding partners.

Collectively, these results significantly expand the range of proteins implicated in the FGF signaling pathway and reveal potential new targets for therapeutic intervention in FGF and Src signaling.

Experimental Procedures {#sec2}
=======================

Cell Culture {#sec2.1}
------------

Mouse NIH 3T3s cells were cultured at 37 °C, 5% CO~2~ in DMEM containing 2 mM [l]{.smallcaps}-Glutamine (Lonza), supplemented with 0.1 mg/mL streptomycin, 0.2 U/mL penicillin (Sigma), and 10% v/v donor bovine serum (Labtech International). Human embryonic kidney epithelial 293T cells were cultured as above; however, donor bovine serum was substituted for 10% v/v fetal calf serum (Labtech International).

SILAC Labeling {#sec2.2}
--------------

For SILAC labeling, NIH 3T3 cells were cultured in amino acid deficient DMEM (Thermo) supplemented with either 0.1 mg/mL isotopically normal [l]{.smallcaps}-Lysine and [l]{.smallcaps}-Arginine (Sigma) or "heavy" ^13^C~6~[l]{.smallcaps}-Lysine and ^13^C~6~^15^N~4~[l]{.smallcaps}-Arginine (Goss Scientific), 10% dialyzed FBS (Thermo), 2 mM [l]{.smallcaps}-Glutamine, 0.1 mg/mL streptomycin, and 0.2 U/ml penicillin. 293T cells were cultured as above, with the addition of 0.5 mg/mL proline (Sigma) in the media.([@ref31]) Cells were grown for at least five doubling times prior to use in order for the cells to fully incorporate the labeled amino acids.

Cloning and Transfection {#sec2.3}
------------------------

The human open reading frame for Dok1 was supplied in a Gateway (Invitrogen) pDONR vector from Open Biosystems. The insert encoding Dok1 was cloned into the Gateway compatible mammalian expression vector, Myc-PRK5 (gift from Laura Machesky) using Gateway cloning. Cells were transfected using Genejuice (Novagen) according to manufacturers' instructions and allowed to overexpress transfected protein for 48 h.

Cell Treatment and Cell Lysis {#sec2.4}
-----------------------------

Following overnight serum starvation in media containing 0.1% serum, cells were either pretreated with 25 μM SU6656 for 1 h, followed by addition of 2 mM sodium pervanadate for 20 min, and then 20 ng/mL FGF2 for 30 min, or treated as above in the absence of SU6656. Prior to lysis, cells were washed twice in cold phosphate-buffered saline (PBS) and then lysed at 4 °C in 1 mL lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 (w/v), 1 mM Na~3~VO~4~, 50 mM NaF, 25 mM β-glycerophosphate and 1 tablet of protease inhibitor mixture (Roche Molecular Diagnostics) per 10 mL of buffer) per 175-cm^2^ flask of cells. After incubation on ice for 30 min, the lysates were centrifuged at 15 000× *g* at 4 °C for 20 min. Total protein concentrations of the cleared lysates were then determined using the Coomassie (Bradford) Protein Assay Kit (Pierce Biotechnology Inc.), according to the manufacturers' instructions.

Western Blotting {#sec2.5}
----------------

Whole cell lysates were run on 4−12% Bis-Tris gels (Invitrogen). Protein was transferred to FL polyvinylidene difluoride membrane (Millipore Corp.) at 100 V for 1 h 15 min. To block the membranes they were washed in methanol and allowed to dry. Primary antibodies were incubated with the membrane overnight at 4 °C in Odyssey Blocking Buffer (Licor Biosciences) containing 0.1% Tween-20. The blot was washed three times for 15min in PBS/0.1% Tween-20 (PBS-T) and probed with the IRDye conjugated secondary antibody (Licor Biosciences) diluted in Odyssey Blocking Buffer/0.1% Tween-20/0.01% SDS for 1 h at room temperature, in the dark. The membrane was washed three times in PBS-T, followed by a final wash in PBS (no Tween 20). Membranes were visualized using fluorescence detection on the Odyssey Infared Imaging System (Licor Biosciences). Primary antibodies used in this study were obtained from Santa Cruz (FRS2, ERK, ERK pY204) and Cell Signaling Technology (FGFR1 pY653/pY654, FRS2 pY196, Src, Src pY416, AKT, and AKT pT308).

Immunoprecipitation {#sec2.6}
-------------------

For the phosphotyrosine immunoprecipitation (IP), agarose-conjugated antiphosphotyrosine (clone 4G10) antibody (Upstate) was used. Whole cell lysates (WCL) were initially precleared with protein A agarose beads for 30 min at 4 °C (25 mg/100 μL beads) before mixing with antibody-conjugated beads (25 mg WCL/100 μL beads). Following overnight incubation at 4 °C, beads were washed six times in a 100-fold excess of ice-cold PBS. To address reproducibility, four replicates of the SILAC phosphotyrosine IPs were carried out. For Myc-Dok1 IPs, Myc-Dok1 antibody 9E10 (Roche) was conjugated to Protein G Dynabeads, as per manufacturers' instructions (Invitrogen; 10 μg Ab/25 μL Dynabeads), prior to addition of cell lysate. WCLs (10 mg) from the heavy and light cell populations were immunoprecipitated separately. WCLs were mixed at 4 °C with conjugated beads (10 mg/170 μL conjugated beads) for 1 h and beads were washed twice in a 20-fold excess of lysis buffer. Beads from both "heavy" and "light" IPs were then mixed and washed a further three times, again in a 20-fold excess of lysis buffer. Following addition of reduced sample buffer, protein samples were run on 4−12% Bis-Tris gels (Invitrogen) and Coomassie stained. Two replicates of each Myc-Dok1 IP were carried out and samples from each IP were analyzed in duplicate.

Trypsin Digestion and Phosphopeptide Enrichment of Samples {#sec2.7}
----------------------------------------------------------

Following the phosphotyrosine IPs, the agarose-conjugated beads were resuspended in 8 M urea, 50 mM ammonium bicarbonate. The beads were then heated at 95 °C for 5 min and eluted proteins were removed in the supernatant after centrifugation. The protein mixtures were diluted to 1 M urea, reduced (4 mM DTT) and alkylated (8 mM iodoacetamide) in 50 mM ammonium bicarbonate prior to overnight trypsin digestion (1:100 enzyme:protein; Trypsin Gold; Promega, Madison, WI).

Following the Myc-Dok1 IPs, excised bands from Coomassie-stained gels were destained, reduced (10 mM DTT) and alkylated (55 mM iodoacetamide) in 25 mM ammonium bicarbonate prior to overnight in-gel trypsin digestion (12.5 ng/μL; Trypsin Gold; Promega, Madison, WI).

Digested samples were acidified by addition of trifluoroacetic acid (0.5% final volume). Peptides from the anti-pY IPs were desalted (Peptide concentration and desalting Macrotrap; Michrom Bioresources, Pleasanton, CA) and dried by vacuum centrifugation. Phosphopeptides were enriched using TiO~2~ as described.([@ref23]) The resulting peptide mixtures were analyzed by liquid chromatography tandem mass spectrometry (LC−MS/MS).

Mass Spectrometry {#sec2.8}
-----------------

Online liquid chromatography was performed by use of a Micro AS autosampler and Surveyor MS pump (Thermo Electron, Bremen, Germany). Peptides were loaded onto a 75 μm (internal diameter) Integrafrit (New Objective, Woburn, MA) C8 resolving column (length 10 cm) and separated over a 40 min gradient from 0% to 40% acetonitrile (Baker, Holland). Peptides eluted directly (∼300 nL/min) via a Triversa nanospray source (Advion Biosciences, Ithaca, NY) into a 7 T LTQ FT mass spectrometer (Thermo Fisher Scientific). The mass spectrometer alternated between a full FT-MS scan (*m*/*z* 395−1600), subsequent CID MS/MS scans of the five most abundant ions, and, if a neutral loss of 98 Da from the precursor ion was observed in the CID mass spectrum, an MS^3^ scan of the neutral loss ion. Survey scans were acquired in the ICR cell with a resolution of 100 000 at *m*/*z* 400. Precursor ions were isolated and subjected to CID in the linear ion trap. Isolation width was 3 Th. Only multiply charged precursor ions were selected for MS/MS. CID was performed with helium gas at a normalized collision energy of 35%. Precursor ions were activated for 30 ms. Data acquisition was controlled by Xcalibur 2.0 software.

Identification and Quantification of Peptide and Proteins {#sec2.9}
---------------------------------------------------------

Mass spectra were processed using the MaxQuant software (version 1.0.12.31).^[@ref22],[@ref32]^ Data were searched, using MASCOT version 2.2 (Matrix Science), against a concatenated database consisting of the mouse or human IPI database supplemented with common contaminants (including keratins, trypsin, BSA) and the reversed-sequence version of the same database. The mouse database contained 111 130 protein entries (55 565 of which were reversed-sequence versions). The human database contained 148 380 protein entries (74 190 of which were reversed-sequence versions). The search parameters were: minimum peptide length 6, peptide tolerance 30 ppm, mass tolerance 0.5 Da, cleavage enzyme trypsin/P, and a total of 2 missed cleavages were allowed. Carbamidomethyl (C) was set as a fixed modification and oxidation (M) and acetylation (Protein N-term) were set as variable modifications. When searching for phosphopeptides, Phospho (ST) and Phospho (Y) were also set as variable modifications. The appropriate SILAC labels were selected and the maximum labeled amino acids was set to 3.

For identification of phosphorylation sites, all experiments (phosphotyrosine IP and Myc-Dok1 IP) were filtered to have a peptide false-discovery rate (FDR) below 1%. The Myc-Dok1 IP experiments were further required to have a protein FDR below 1%. Within the MaxQuant output, phosphorylation sites were considered to be localized correctly if the localization score (PTM score) was at least 0.80 (80%). Further parameters and settings are detailed in the Supplementary Methods.

Phosphorylation Site Localization using SLoMo {#sec2.10}
---------------------------------------------

DTA files were created from the raw data using Bioworks 3.3.1 (Thermo Fisher Scientific Inc.). The DTA files were searched using Mascot with the search parameters as described above. Mascot search results were exported as a pepxml file and this file was analyzed using the SloMo software.([@ref35])

Results and Discussion {#sec3}
======================

Identification of Src Family Kinase-Mediated Phosphorylation Events, in the Presence of FGF2 {#sec3.1}
--------------------------------------------------------------------------------------------

Activation of fibroblast growth factor receptors (FGFRs) by FGF2 initiates a cascade of reversible phosphorylation events on both the receptor and on downstream effector proteins.([@ref6]) Although the core signaling events during FGFR signaling are well established, relatively little has been published on the global analysis of changes in protein levels and phosphorylation events.^[@ref13],[@ref24],[@ref25]^ Our aim was to generate a data set of tyrosine phosphorylated proteins that could be mapped to the FGF signaling pathway.

We have chosen to focus specifically on a network of proteins that may be involved in FGFR trafficking and endocytosis: the Src-mediated network. Src family kinases (SFKs) have long been implicated in signaling by a variety of receptor tyrosine kinases (RTKs), including FGFR, epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), and hepatocyte growth factor (HGFR).([@ref34]) In FGFR signaling, upon activation of receptor by FGF2, Src is recruited via the adaptor protein, FRS2 and also becomes activated.^[@ref14],[@ref35]^ Active Src then plays a role in regulation of the activation and transport of FGFR from and to the plasma membrane via the Src-regulated endosomal-actin pathway.^[@ref14],[@ref36]^ Considering the role of Src in trafficking of FGFRs, we decided to further characterize SFK-mediated phosphorylation events that may be downstream of FGFR, using a SILAC quantitative phosphoproteomics approach coupled with chemical inhibition of SFK activity.

Prior to FGF2 stimulation, cells were treated with sodium pervanadate to inhibit tyrosine phosphatase activity, thereby increasing the levels of transiently phosphorylated phosphotyrosine proteins.([@ref27]) As phosphorylation events are the result of a balance between kinase and phosphatase activities, inhibition of phosphatase activity will allow a history of kinase-mediated phosphorylation events to remain during the course of the experiment. Activation of FGFR, as measured by phosphorylation on residues 653 and 654, is rapid in response to FGF2 and peaks between 3 and 10 min (Figure [1](#fig1){ref-type="fig"}). Phosphorylation of well-characterized downstream target proteins of FGFR, such as FRS2, Src, AKT and ERK peaks between 10 and 30 min. We chose to stimulate NIH 3T3 cells with FGF2 for 30 min, in the presence or absence of the selective Src family kinase inhibitor, SU6656,([@ref37]) in order to investigate phosphorylation events downstream of FGFR-dependent phosphorylation of SFKs. This was followed by quantitative analysis of the SFK-dependent phosphorylation events. Without overexpressing FGFR, as has been done previously to study the phospho-proteome of FGF signaling,^[@ref24],[@ref25]^ and in the absence of pervanadate treatment, levels of phosphopeptides remained too low for mass spectrometric detection (data not shown).

![Profiles of phosphorylation events in the presence of FGF2. NIH 3T3s were stimulated with 20 ng/mL FGF2 for varying lengths of time. Western blot analysis was carried out on whole cell lysates using antibodies against indicated proteins and phospho-proteins.](pr-2009-010475_0001){#fig1}

We performed four independent experiments, three utilizing both heavy arginine and lysine SILAC labels and one utilizing only heavy lysine. From these experiments we identified 711 (redundant) peptides, including 430 (redundant) phosphotyrosine peptides (Supplementary Table S1, [Supporting Information](#si1){ref-type="notes"}). Representative mass spectra for two of the identified phosphopeptides are shown in Figure [2](#fig2){ref-type="fig"} (see [Supporting Information](#si1){ref-type="notes"} for additional spectra). Given the complexity of the starting sample (mouse whole cell lysate) and the variability introduced during the phosphotyrosine IP and phosphopeptide enrichment steps, we expected considerable variation between experiments. The overlap between the four experiments is shown in Figure S1 ([Supporting Information](#si1){ref-type="notes"}): 50% of the phosphotyrosine peptides were identified in 2 or more experiments, while 30% were identified in 3 or more experiments. A total of 131 unique tyrosine phosphorylation sites were identified from 63 distinct proteins. Of the total 131 phosphotyrosine sites, 6 (5%) are novel, unpublished sites according to the PhosphoSitePlus database at [www.phosphosite.org](www.phosphosite.org).([@ref38])

![Representative mass spectra for identification and site localization of tyrosine phosphorylation. (a) Afadin is phosphorylated at pY203. (b) Catenin delta-1 is phosphorylated at pY865. Peptides are labeled with 13C(6),15N(4) Arg and 13C(6) Lys. pY indicates phosphotyrosine.](pr-2009-010475_0002){#fig2}

Of the peptides identified, a total of 506 were assigned a SILAC ratio in MaxQuant, the remainder were not, due to peptide levels being undetectable in one of the cell populations or due to the peptide not containing a lysine (singly labeled experiment). The three experiments utilizing both arginine and lysine SILAC labels gave a total of 433 phosphopeptide identifications, of which 303 were tyrosine phosphorylated and were assigned a SILAC ratio (Supplementary Table S2, [Supporting Information](#si1){ref-type="notes"}). The overlap between these three experiments for the 303 phosphotyrosine peptides (139 nonredundant phosphotyrosine peptides) is shown in Figure S2 ([Supporting Information](#si1){ref-type="notes"}): again, 50% of the phosphotyrosine peptides were identified in two or more experiments and 25% were identified in all three experiments.

A total of 80 tyrosine phosphorylation sites show a significant (*p* \< 0.05) increase or decrease in abundance in the phosphotyrosine immunoprecipitates due to the presence of the SFK inhibitor (Table [1](#tbl1){ref-type="table"}). Several of the SFK-dependent tyrosine phosphorylation sites identified are on proteins known to be regulated by Src, including BAIP2, ZO1, paxillin, caveolin, Dok1, EGFR, Eps8, STAM2, cortactin, FAK1, PDGFRα, p130Cas, p120 catenin, tensin, PLCγ, and SHIP2.^[@ref28],[@ref39]−[@ref41]^ This validates the strength of our approach for identifying Src-targets. For many of these proteins, the specific site(s) of tyrosine phosphorylation have not been previously identified as SFK phosphorylation sites according to the Human Protein Reference Database.([@ref42]) Furthermore, our data agrees with previous phosphoproteomic studies that have examined the phosphotyrosine peptide profile in 3T3 mouse fibroblasts expressing a constitutively active Src mutant, SrcY529F^[@ref26],[@ref29]^ in that we identify several Src-dependent phosphotyrosine sites that were also frequently identified in these Src-transformed cells. These include: p120 catenin pY96, pY221, pY228, pY257, pY280; p130cas pY132; Dok1 pY295; cortactin pY215, and ZO1 pY1164, pY1177.

###### Phosphotyrosine Peptides Significantly Changed Due to the Presence of SU6656[a](#tbl1-fn1){ref-type="table-fn"}

  protein                                                          phosphopeptide                              phosphosite(s)   SILAC ratio   \% variability
  ---------------------------------------------------------------- ------------------------------------------- ---------------- ------------- ----------------
  ABI1 Abelson interactor 1                                        NTPpYKTLEPVKPPTVPNDpYMTSPAR                 pY197, pY212     0.083         56.942
                                                                   TLEPVKPPTVPNDpYMTSPAR                       pY212            0.561         79.405
  ABLM1 Actin-binding LIM protein 1                                STSQGSINSPVpYSR                             pY505            0.195          
  AFAD Afadin                                                      LAAEVpYKDMPETSFTR                           pY203            0.259         85.353
                                                                   EpYFTFPASK                                  pY1230           0.482         41.237
                                                                   SQEELREEKVpYQLER                            pY1285           0.202         43.666
  AHNAK Ahnak protein                                              VKGEpYDVTMPK                                pY963            0.316          
  BAIP2 Insulin receptor substrate p53                             LSDSpYSNTLPVRK                              pY338            0.164          
  BCAR1 p130cas                                                    TQQGLpYQAPGPNPQFQSPPAK                      pY132            0.221          
                                                                   GLLSSSHHSVpYDVPPSVSK                        pY310            0.577         22.478
                                                                   RPGPGTLpYDVPR                               pY391            0.326         23.664
  CASL CRK-associated substrate-related protein                    LpYQVPNSQAASR                               pY91             0.352         38.486
  CAV1 Caveolin-1                                                  YVDSEGHLpYTVPIR                             pY14             0.378         3.108
  CDH11 Cadherin-11                                                KDIKPEpYQYMPR                               pY700            0.265         13.550
  CDV3 Protein CDV3                                                KTPQGPPEIpYSDTQFPSLQSTAK                    pY213            0.143         33.332
                                                                   LQLDNQpYAVLENQK                             pY267            0.162          
  CTND1 Catenin delta-1                                            LNGPQDHNHLLpYSTIPR                          pY96             0.530         32.209
                                                                   TVQPVPMGPDGLPVDASAVSNNpYIQTLGR              pY174            0.382         17.762
                                                                   NFHYPPDGYGRHYEDGpYPGGSDNpYGSLSR             pY221, pY228     0.173         23.705
                                                                   HYEDGYPGGSDNpYGSLSR                         pY228            3.003         21.770
                                                                   YRPSMEGpYR                                  pY248            0.155         44.702
                                                                   QDVpYGPQPQVR                                pY257            0.254         30.310
                                                                   FHPEPpYGLEDDQR                              pY280            0.289         60.708
                                                                   SQSSHSpYDDSTLPLIDR                          pY865            0.116         45.682
                                                                   SLDNNpYSTLNERGDHNR                          pY904            0.429         35.851
  DBNL Actin-binding protein 1                                     ESTSFQDVGPQAPVGSVpYQK                       pY162            0.092         18.622
                                                                   QLTQPETSpYGREPTAPVSR                        pY305            0.044         53.280
  DOK1 Docking protein 1                                           TVPPPVPQDPLGSPPALpYAEPLDSLR                 pY295            0.579         19.218
  E41L3 Band 4.1-like protein 3                                    SLDGEVGTGQpYATTK                            pY453            0.353          
  EGFR Epidermal growth factor receptor                            LLGAEEKEpYHAEGGKVPIK                        pY871            0.203         40.247
                                                                   RPAGSVQNPVpYHNQPLHPAPGR                     pY1110           0.385         39.984
                                                                   GPTAENAEpYLR                                pY1197           0.555         44.154
  EMD Emerin                                                       TpYGEPESVGMSK                               pY106            0.074         25.481
                                                                   LIYGQDSApYQSIAHYRPISNVSR                    pY161            0.089         33.376
                                                                   LIYGQDSAYQSIAHpYRPISNVSR                    pY167            0.054          
  EPS8 Epidermal growth factor receptor kinase                     STPNHQVDRNpYDAVK                            pY524            0.504          
  FAK1 Focal adhesion kinase 1                                     AAApYLDPNLNHTPSSSTK                         pY4              0.174         21.969
                                                                   YMEDSTpYpYKASK                              pY614, pY615     0.343         15.339
  IFITM3 Interferon-induced transmembrane protein 3                MNHTSQAFITAASGGQPPNpYER                     pY20             0.576         18.836
                                                                   IKEEpYEVAEMGAPHGSASVR                       pY27             0.433         26.578
  KIRR1 Kin of IRRE-like protein 1                                 AVLpYADYRAPGPTR                             pY654            2.348          
                                                                   AVLYADpYRAPGPTR                             pY657            0.350          
                                                                   AVLpYADpYRAPGPTR                            pY654, pY657     0.432         19.452
                                                                   TPpYEApYDPIGK                               pY753, pY756     0.467          
                                                                   TPYEApYDPIGK                                pY756            1.771         20.387
                                                                   FSYTSQHSDpYGQRFQQR                          pY777            0.484          
  LPP Lipoma-preferred partner homologue                           SAQPSPHpYMAGPSSGQIpYGPGPR                   pY235, pY245     0.032         173.794
                                                                   SAQPSPHYMAGPSSGQIpYGPGPR                    pY245            0.063         111.089
                                                                   YpYEPYYAAGPSYGGR                            pY297            0.266          
                                                                   YYEPYpYAAGPSYGGR                            pY302            0.269         10.928
                                                                   SEGDTApYGQQVQPNTWK                          pY318            0.137         96.380
                                                                   EAApYAPPASGNQNHPGMYPVSGPK                   pY333            0.071         65.503
  PARD3 Partitioning-defective 3 homologue                         ESVSTSSDQPSpYSLER                           pY969            0.118          
                                                                   ERDpYAEIQDFHR                               pY1076           0.514         16.397
  PAXI Paxillin                                                    YAHQQPPSPLPVpYSSSAK                         pY88             0.395         31.523
                                                                   AGEEEHVpYSFPNK                              pY118            0.501         24.616
  PCDHGC3 Protocadherin gamma C3                                   APVSSLpYR                                   pY735            0.528          
  PEAR1 Platelet endothelial aggregation receptor 1                ESGpYVEMKGPPSVSPPR                          pY41             0.138          
  PGFRA Platelet-derived growth factor receptor alpha              QADTTQpYVPMLER                              pY742            0.443         32.533
                                                                   SLpYDRPASYK                                 pY762            0.410         32.001
                                                                   LSADSGpYIIPLPDIDPVPEEEDLGKR                 pY1018           0.162         38.489
  PKP4 Plakophilin-4                                               LQHQQLpYpYQDDSTRK                           pY1114, pY1115   0.387         5.041
  PLCG1 PLCγ                                                       pYQQPFEDFR                                  pY1253           0.518         5.699
  Q3UGC2 Cortactin, isoform CRA_e                                  HESQQDpYAKGFGGK                             pY302            0.291         17.822
  RBM3 RNA-binding motif protein 3                                 YDSRPGGYGpYGYGR                             pY124            0.204          
                                                                   YSGGNYRDNpYDN                               pY151            0.318         44.561
  SCAM3 Scamp3                                                     NpYGSYSTQASAAAATAELLK                       pY85             0.333         30.094
  SHIP2 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2   TLSEVDpYAPGPGR                              pY1136           0.560         31.372
  STAM2 Signal transducing adapter molecule 2                      LVNEAPVpYSVYSK                              pY371            0.113         27.025
  SRC8 Cortactin                                                   HASQKDpYSSGFGGK                             pY154            0.201          
                                                                   NASTFEEVVQVPSApYQK                          pY334            0.085         32.432
  TBCB Tubulin folding cofactor B                                  LGEpYEDVSKVEK                               pY98             0.172          
  TENC1 Tensin-2                                                   GPLDGSPpYAQVQR                              pY483            0.245         38.913
                                                                   LALPTAALpYGLR                               pY705            0.204          
  TENS1 Tensin-1                                                   HAApYGGYSTPEDR                              pY1477           0.293          
  TERA Transitional endoplasmic reticulum ATPase                   GFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLpYG   pY805            0.111          
  ZDHC8 Probable palmitoyltransferase ZDHHC8                       KVSGVGGTTpYEISV                             pY711            0.432          
  ZO1 Tight junction protein ZO-1                                  YRPEAQPpYSSTGPK                             pY1177           0.038         62.278
                                                                   SpYEQVPPPGFTSK                              pY1198           0.208         58.171
                                                                   HEEQPAPApYEVHNR                             pY1164           0.112         50.945

Variability (%) was calculated using the standard deviation of the natural logarithms of the SILAC ratios, multiplied by 100.

Abi1, CDV3, afadin, and LPP have been identified as possible Src substrates in a previous phosphoproteomic study using SILAC to compare tyrosine phosphorylated proteins in SW60-Src with those in SW60 cells.([@ref28]) Our data provides further evidence that these proteins are Src substrates and also maps the specific phosphorylation sites on these proteins that are regulated by Src.

In addition, a large percentage (\>30%) of the Src-dependent phosphotyrosine sites were found in proteins not previously reported to be regulated by Src. These include the proteins ABLM1, CASL, Cadherin-11, Drebrin-like protein, Emerin, PARD3, PEAR1, RMB3, and TERA.

We have not used overexpression of FGFR in these studies; therefore, we do not expect complete overlap with previous phospho-proteomic studies of FGF signaling that have relied on overexpressed FGFR.^[@ref24],[@ref25]^ Ten FGFR1-associated tyrosine phosphorylated proteins were identified in these overexpression studies of which four were identified here as SFK-substrates (cortactin, p130Cas, PLCγ and paxillin). Tyrosine phosphorylation of these proteins, therefore, appears to be both downstream of FGFR and SFK activation. An additional 20 proteins were shown to be enriched in a phosphotyrosine IP as a consequence of FGF-stimulation, however, tyrosine phosphorylation sites were not identified.([@ref24]) Of these additional proteins, we identify both FAK1 and SHIP2 as SFK-substrates, and also RSK2.

Src Family Kinase-Dependent Dok1 Phosphorylation Sites {#sec3.2}
------------------------------------------------------

Although the global SFK-dependent phosphorylation data set provides evidence for SFK-mediated tyrosine phosphorylation on a large number of proteins, it provides limited mapping of phosphorylation sites on individual proteins. This is not unexpected, given the limited dynamic range of proteomic experiments and can be addressed through targeted analysis of particular proteins, enabling identification of lower stoichiometry sites of phosphorylation. We apply this further step to localize additional sites of phosphorylation on the protein Dok1. We note, however, that this step in our approach can be used to further characterize any of the proteins showing SFK-dependency that we have identified in our global analysis.

We chose to study Dok1 based on its reported interaction and regulation by Src^[@ref43]−[@ref46]^ and also its role in tyrosine kinase receptor mediated signaling.^[@ref45],[@ref47],[@ref48]^ Dok1 is an adaptor protein involved in protein complex formation during cell signaling and is a substrate for many protein tyrosine kinases. Dok1 is known to be phosphorylated by activated Src^[@ref43],[@ref45],[@ref46]^ and also by activated EGF receptor([@ref45]) and insulin receptor.^[@ref47],[@ref48]^ Upon tyrosine phosphorylation, Dok1 recruits a variety of SH2-containing proteins and is therefore an attractive candidate for mediation of FGF signaling.

To map phosphorylation sites of Dok1 and determine which of these phosphorylation events are SFK-dependent, we carried out a SILAC experiment in which Myc-Dok1 was overexpressed and immunoprecipitated in 293T cells. Heavy and light populations were stimulated with sodium pervanadate and FGF2 ± SU6656, as described above. Phosphopeptide enrichment was carried out on the immunoprecipitated Dok1.

The potential for distinct phosphorylation sites with distinct patterns of regulation on the same tryptic peptide is an important factor to take into account when analyzing data such as these.([@ref49]) Initial examination of the MaxQuant output revealed several identical peptides with a number of possible phosphorylation sites. In one particular case, the peptide, LPSPPGPQELLDSPPALYAEPLDSLR was separately identified as being phosphorylated on the first serine, the second serine, or the tyrosine residue. The SILAC ratios were highly variable between peptides where the phospho-group had been allocated the same localization, and after averaging ratios for each modification the data suggested that the SILAC ratios were all unchanged in the presence of SU6656. These data prompted us to use the SLoMo software([@ref33]) to reanalyze the site-localization on these enriched Dok1 phosphopeptides. Analysis of the SLoMo output reveals that the three phosphopeptides are indeed present and are partially coeluting. Further manual inspection of the spectra reveals that only the phosphotyrosine version is differentially regulated in the presence of SU6656 (Figure [3](#fig3){ref-type="fig"}).

![Partial co-elution of isobaric phosphopeptides. The Dok1 peptide LPSPPGPQELLDSPPALYAEPLDSLR is present in three different singly phosphorylated forms, with phosphorylation occurring at Ser281, Ser291, and Tyr296. The selected-ion chromatogram for the \[M + 3H\]^3+^ light precursor is shown. Comparison of the heavy/light ratios for the three versions indicates that only Tyr296 is Src-dependent.](pr-2009-010475_0003){#fig3}

A total of 12 distinct sites of phosphorylation (4 serines, and 8 tyrosines) on Dok1 were identified. According to the PhosphositePlus database,([@ref38]) all but one has been published previously, the exception being Ser48. Out of the 12 identified phosphosites, 9 (Ser48, Tyr 296, Tyr337, Tyr341, Tyr362, Tyr377, Tyr398, Tyr409, Tyr449) had a significantly reduced SILAC ratio (*p* \< 0.05; Table [2](#tbl2){ref-type="table"}), indicating that these particular phosphorylation sites within Dok1 are regulated via Src family kinases.

###### Phosphopeptide Mapping of Dok1[a](#tbl2-fn1){ref-type="table-fn"}

  phosphosite(s)                                                   modified peptide(s)                                       localization score (SLoMo)   ratio H/L count   ratio H/L   \% variability
  ---------------------------------------------------------------- --------------------------------------------------------- ---------------------------- ----------------- ----------- ----------------
  Peptides with reduced SILAC ratios in the presence of SU6656                                                                                                                          
  Ser48                                                            LEFFDHKGSpSSGGGR                                          25.6                         2                 0.377       3.308
  Tyr296                                                           LPSPPGPQELLDSPPALpYAEPLDSLR                               75                           3                 0.136       108.796
  Tyr337                                                           KKPLpYWDLYEHAQQQLLK                                       62.1                         2                 0.033       38.622
  Tyr341                                                           KKPLYWDLpYEHAQQQLLKKPLYWDLpYEHAQQQLLK                     100.4                        10                0.018       76.261
  Tyr362                                                           EDPIpYDEPEGLAPVPPQGLYDLPRLTDPKEDPIpYDEPEGLAPVPPQGLYDLPR   142.5                        9                 0.198       16.081
  Tyr377                                                           EDPIYDEPEGLAPVPPQGLpYDLPRLTDPKEDPIYDEPEGLAPVPPQGLpYDLPR   185.5                        5                 0.099       142.837
  Tyr398                                                           VKEEGpYELPYNPATDDYAVPPPR                                  30.6                         1                 0.084        
  Tyr409                                                           EEGYELPYNPATDDpYAVPPPRVKEEGYELPYNPATDDpYAVPPPR            79.6                         20                0.142       43.88
  Tyr449                                                           SHNSALpYSQVQK                                             72.1                         21                0.167       118.322
  Tyr337;Tyr341                                                    KPLpYWDLpYEHAQQQLLK                                       One possibility              1                 0.071        
  Tyr362;Tyr377                                                    LTDPKEDPIpYDEPEGLAPVPPQGLpYDLPR                           18.6                         4                 0.030       60.981
  Tyr398;Tyr409                                                    VKEEGpYELPYNPATDDpYAVPPPR                                 34.1                         3                 0.024       23.142
  Peptides with unchanged SILAC ratios in the presence of SU6656                                                                                                                        
  Ser269                                                           ADpSHEGEVAEGKAGQGHDVLRADpSHEGEVAEGK                       One possibility              11                0.880       15.969
  Ser281                                                           LPpSPPGPQELLDSPPALYAEPLDSLR                               39.7                         5                 0.772       30.703
  Ser291                                                           LPSPPGPQELLDpSPPALYAEPLDSLR                               84.2                         8                 0.899       33.448

SLoMo score = −10 × (log(*p*). A score of 19 corresponds to a localization confidence with *p* = 0.0126.([@ref33])

Although many sites of phosphorylation have been previously identified on Dok1, only three tyrosine residues (Y296, Y362, and Y449) have been reported to be direct sites of Src-mediated phosphorylation, with residue 362 described as a binding site for Src.^[@ref46],[@ref50]^ We have identified these 3 tyrosine phosphorylation sites, together with a further 5 tyrosine residues whose phosphorylation is decreased in the presence of SU6656. In addition, the novel phosphoserine 48 residue that we have identified also shows SFK-dependency. Both Src-dependent phosphorylation sites of Dok1, and sites not previously identified as Src-dependent phosphorylation sites, have been implicated in recruitment of proteins. Phosphorylation of residue 362 is involved in Nck recruitment,([@ref48]) and phosphorylation of Tyr296, Tyr315, Tyr362, Tyr398, and Tyr409, has been implicated in binding to Ras-GAP.^[@ref48],[@ref51],[@ref52]^

Src Family Kinase-Dependent Dok1 Binding Partners {#sec3.3}
-------------------------------------------------

Using this targeted, quantitative SILAC method, not only have we identified SFK-dependent Dok1 phosphorylation sites, but, using the same IP sample we can also identify the SFK-dependency of Dok1 interactions with binding partners. In order to identify specific binding partners of Dok1 and to determine which proteins are present as a consequence of nonspecific interactions, we carried out a parallel SILAC experiment comparing untransfected cells with cells in which Myc-Dok1 was overexpressed. All cells were treated with sodium pervanadate and FGF2 as described above.

A total of 329 proteins were identified from the IP in which Myc-Dok1 transfected cells were compared to untransfected cells (Supplementary Table S3, [Supporting Information](#si1){ref-type="notes"}). The false-discovery rate was controlled at below 1%. MaxQuant calculated SILAC ratios for 185 of these proteins. Proteins with SILAC ratios significantly different from the median, as calculated using MaxQuant (*p* \< 0.05), were considered as enriched proteins in either cell population. Those proteins present equally in the transfected and untransfected samples or enriched in the untransfected cell population were considered as contaminants in further IP experiments. Table [3](#tbl3){ref-type="table"} shows the 25 proteins that were enriched in the 293T cells transfected with Dok1. Csk and NCK2, proteins known to interact with Dok1,^[@ref53],[@ref54]^ showed a significantly increased abundance in the 293T-Dok1 cells, as measured by their SILAC ratio. In addition, Grb2, RasGAP, and PLCγ1, all known Dok1 binding partners,([@ref44]) were enriched in the 293T-Dok1 cell population, as measured by the peak intensity. Calculation of SILAC ratios was not possible as no peptides from these proteins were identified in the untransfected cell population.

###### Proteins with Increased SILAC Ratios Due to Enrichment in Myc-Dok1 Transfected Cells

  protein IDs   protein names                                                        unique peptides (seq/mod/labels)   sequence coverage (%)   ratio H/L   ratio H/L significance
  ------------- -------------------------------------------------------------------- ---------------------------------- ----------------------- ----------- ------------------------
  IPI00306531   NCK2                                                                 6                                  9.5                     2.626       4.27 × 10^2^
  IPI00449049   Poly \[ADP-ribose\] polymerase 1 (PARP1)                             2                                  2.4                     2.750       3.57 × 10^2^
  IPI00887678   Peptidyl-prolyl cis−trans isomerase A                                6                                  27.4                    2.762       3.51 × 10^2^
  IPI00007188   ADP/ATP translocase 2                                                11                                 25.8                    3.070       2.27 × 10^2^
  IPI00293655   ATP-dependent RNA helicase DDX1                                      5                                  6.4                     3.363       1.52 × 10^2^
  IPI00396435   Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15   2                                  1.5                     3.391       1.47 × 10^2^
  IPI00296337   DNA-dependent protein kinase catalytic subunit                       4                                  1.2                     3.572       1.15 × 10^2^
  IPI00410693   Plasminogen activator inhibitor 1 RNA-binding protein                3                                  6.6                     3.609       1.10 × 10^2^
  IPI00215790   60S ribosomal protein L38                                            4                                  47.1                    3.842       8.11 × 10^3^
  IPI00386604   Putative uncharacterized protein                                     6                                  15                      4.603       3.18 × 10^3^
  IPI00026781   Fatty acid synthase                                                  7                                  3.3                     5.025       1.95 × 10^3^
  IPI00018350   DNA replication licensing factor MCM5                                6                                  10.6                    5.671       9.55 × 10^4^
  IPI00376798   60S ribosomal protein L11                                            9                                  40.4                    6.067       6.29 × 10^4^
  IPI00024067   Clathrin heavy chain 1                                               3                                  2.5                     6.126       5.92 × 10^4^
  IPI00396485   Elongation factor 1-alpha 1                                          12                                 16                      6.882       2.78 × 10^4^
  IPI00016610   Poly(rC)-binding protein 1                                           2                                  6.7                     8.265       7.81 × 10^5^
  IPI00013214   DNA replication licensing factor MCM3                                9                                  10.7                    12.162      3.81 × 10^5^
  IPI00156005   RNA-binding protein Nova-2                                           1                                  2.2                     19.196      5.92 × 10^8^
  IPI00013212   Tyrosine-protein kinase CSK                                          14                                 29.6                    19.795      4.37 × 10^8^
  IPI00186290   Elongation factor 2                                                  11                                 11.9                    28.888      8.16 × 10^10^
  IPI00000874   Peroxiredoxin-1                                                      8                                  43.2                    30.256      4.86 × 10^10^
  IPI00216746   Heterogeneous nuclear ribonucleoprotein K                            4                                  13.6                    30.681      4.15 × 10^10^
  IPI00027350   Peroxiredoxin-2                                                      4                                  27.8                    31.323      3.28 × 10^10^
  IPI00011200   D-3-phosphoglycerate dehydrogenase                                   13                                 25.5                    77.030      3.25 × 10^15^
  IPI00015287   Docking protein 1 (Dok1)                                             53                                 80.5                    82.827      1.15 × 10^15^

Of the identified proteins enriched in the 293T-Dok1 cells ∼40% are nuclear proteins that are involved in events such as transcription, splicing, DNA replication and nucleic acid metabolism. Although Dok1 is predominantly a cytoplasmic/membrane protein, it has also been shown that a proportion of it is found in the nucleus.([@ref50]) The function of Dok1 in the nucleus has not yet been determined, but it may be that these nuclear proteins are linked to its nuclear function. Alternatively, these nuclear proteins may be binding nonspecifically to overexpressed Dok1.

Dok1 is known to function as an adaptor protein in insulin signaling and has recently been shown to have a role in energy metabolism, mediating adipocyte hypertrophy and obesity through modulation of peroxisome proliferator-activated receptor- γ (PPAR-γ) phosphorylation.([@ref55]) PPAR-γ is a nuclear receptor that mediates the metabolism of fatty acids and induces genes related to fatty acid metabolism. Antagonising PPAR-γ has been shown to result in a decrease in peroxiredoxin.([@ref56]) Interestingly, we identified enriched fatty acid synthase (FAS), peroxiredoxin-1 (PRDX-1) and peroxiredoxin-2 (PRDX-2) as putative Dok1 interactors. It is tempting to speculate that these proteins may link Dok1 to PPAR- γ and their role in energy metabolism.

The Dok1 SILAC experiment in the presence and absence of SU6656, allowed us to identify Dok1 binding partners whose interaction with Dok1 was regulated by SFKs. A total of 341 proteins were identified (\<1% FDR) (Supplementary Table S4, [Supporting Information](#si1){ref-type="notes"}). The Dok1 protein itself had a SILAC ratio of 1.05 (heavy/light, where heavy was SU6656-treated). Of the known binding partners of Dok1, PLCγ1 and NCK2 were significantly enriched in the SU6656-treated cells, with SILAC ratios of 2.04 and 2.30, respectively (Table [4](#tbl4){ref-type="table"}). The enrichment of PLCγ1 and NCK2 in the SU6656 treated cells indicates that the inhibition of SFK activity, and thus phosphorylation events mediated by SFKs, has caused an increase in the amount of these proteins bound to Dok1. RasGAP and Csk were not significantly enriched in either cell population (with SILAC ratios of 0.82 and 1.24, respectively), suggesting that these interactions are not SFK-dependent.

###### Proteins Identified in a Myc-Dok1 Immunoprecipitation whose SILAC Ratios are Significantly Changed Due to the Presence of SU6656

  protein ID                                                       protein names                                                      unique peptides (seq/mod/labels)   sequence coverage (%)   ratio H/L   ratio H/L significance   ratio H~myc-Dok1~/L~untransfected~
  ---------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------- ----------------------- ----------- ------------------------ -------------------------------------
  Proteins with reduced SILAC ratios due to presence of SU6656                                                                                                                                                                        
  IPI00873058                                                      Paired Box 1                                                       2                                  1.9                     0.016       1.05 × 10^−21^           [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00440577                                                      IGKV2−24 protein                                                   1                                  3.8                     0.042       2.26 × 10^−13^           [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00798360                                                      SAP domain containing ribonucleoprotein                            1                                  4.3                     0.373       1.10 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00104050                                                      Thyroid hormone receptor-associated protein 3                      3                                  2.7                     0.391       1.45 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  Proteins with increased SILAC ratios due to presence of SU6656                                                                                                                                                                      
  IPI00001159                                                      Translational activator GCN1                                       5                                  1.4                     1.753       4.37 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00003965                                                      Ubiquitin carboxyl-terminal hydrolase 7                            7                                  4.5                     1.758       4.29 × 10^2^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00031647                                                      Programmed cell death protein 2-like                               2                                  3.4                     1.797       3.69 × 10^2^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00024364                                                      Transportin-1;Importin beta-2                                      5                                  3.8                     1.823       3.34 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00514856                                                      Ubiquitin-associated protein 2-like                                4                                  1.8                     1.834       3.20 × 10^2^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00016932                                                      Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 (SHIP2)   2                                  1.4                     1.870       2.79 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00221012                                                      Probable ubiquitin carboxyl-terminal hydrolase FAF-X               6                                  2.7                     1.954       2.01 × 10^2^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00020729                                                      Insulin receptor substrate 4 (IRS4)                                2                                  2.1                     1.980       1.81 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00383849                                                      Phospholipase C, gamma 1 (PLCγ)                                    8                                  4.3                     2.036       1.46 × 10^2^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00029705                                                      Gamma-tubulin complex component 2                                  1                                  1.2                     2.125       1.03 × 10^2^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00306531                                                      NCK adaptor protein 2                                              1                                  4.5                     2.302       5.11 × 10^3^             2.6
  IPI00217223                                                      Multifunctional protein ADE2                                       3                                  5.8                     2.366       3.97 × 10^3^             [b](#tbl4-fn2){ref-type="table-fn"}
  IPI00410590                                                      LSM14 protein homologue A                                          2                                  2.2                     2.447       2.89 × 10^3^             [a](#tbl4-fn1){ref-type="table-fn"}
  IPI00011631                                                      Centromere/kinetochore protein zw10 homologue                      2                                  3.7                     3.163       1.79 × 10^4^             [a](#tbl4-fn1){ref-type="table-fn"}

Not detected.

Detected only in Dok1 immunoprecipitation and not in untransfected control; therefore, no ratio could be calculated.

For each significant protein hit, their presence in the myc-Dok1 vs untransfected SILAC experiment was checked in order to see whether they may be a contaminant. Where a protein was not significantly enriched in the myc-Dok1 vs untransfected IP (Table [3](#tbl3){ref-type="table"}), the protein was considered a contaminant and removed from the final list (nine proteins). Table [4](#tbl4){ref-type="table"} shows the remaining 14 proteins that were significantly enriched in the SU6656 treated cells and the 4 proteins that were enriched in the non-SU6656 treated cells. A number of proteins are absent in the myc-Dok1 vs untransfected SILAC experiment (Table [4](#tbl4){ref-type="table"}). In these cases, the possibility remains that the protein may not be a true Dok1 interacting partner, an important consideration when selecting proteins for further biological analysis.

The shuttling of Dok1 between the nucleus and cytoplasm has been shown to be dependent on Src-mediated tyrosine phosphorylation.([@ref50]) Phosphorylation of Dok1 by Src causes accumulation of Dok1 in the cytoplasm, assumed to be caused by an inhibition of nuclear import.([@ref50]) Interestingly, our data shows that, in the presence of the SFK inhibitor, SU6656, Dok1 bound to more nuclear proteins than in the absence of SU6656. The inhibition of nuclear import due to Src-phosphorylation is presumably due to a lack of interaction with nuclear import transporters. Our data shows an increased amount of Dok1-bound transportin-1, a nuclear import protein, in the absence of Src-induced phosphorylation, consistent with Src-dependent inhibition of nuclear import. However, we note that transportin-1 was not identified as a Dok1-binding protein in the previous experiment; therefore, we cannot be certain that this is a true Dok1 interactor.

IRS4 and SHIP2 were also found enriched in SU6656 treated cells, suggesting that they may bind to Dok1 directly or indirectly in a SFK-dependent manner. Dok1 has not previously been linked to either protein, although all three proteins play a role in insulin signaling^[@ref47],[@ref48],[@ref57],[@ref58]^ and both IRS4 and SHIP2 play a role in FGF/FGFR signaling.([@ref24]) Although a direct link between Dok1 and IRS4 has not been previously reported, IRS4 is known to interact with CRKL, which is also a known binding partner of Dok1.([@ref59]) The quantitative proteomics approach described here has not only identified additional putative, binding partners of Dok1 but has also provided information about the regulation of these interactions by SFKs. Future studies will be needed to investigate the role of the novel SFK-dependent phosphorylation sites in these interactions.

Conclusions {#sec4}
===========

We have implemented a differential phosphoproteomics approach for dissection of the SFK-mediated interaction network within the FGF signaling pathway. We have focused on those phosphorylation sites which are dependent on activation of SFK activity and then on Dok1, with the identification of both SFK-dependent and independent sites of phosphorylation, and SFK-dependent Dok1 binding partners. The study has revealed the phosphorylation of multiple downstream kinases and adaptor/scaffolding proteins and has identified a significant number of proteins potentially involved in FGF signaling for further functional scrutiny. We note that the final protein-targeted step in our approach can be used to further characterize any of the proteins showing SFK-dependency that we have identified in our global analysis. Indeed, data from such experiments could be combined to provide a detailed tyrosine phosphorylation map of events occurring within the Src-mediated node of FGFR signaling. The experimental approach employed in this study is readily applicable to deeper analysis of both the FGF and other receptor tyrosine kinases.

Supplementary Methods {#sec5}
=====================

Peptide and Protein Identification and Quantitation {#sec5.1}
---------------------------------------------------

### Antiphosphotyrosine IP (SILAC) {#sec5.1.1}

Fifteen raw files were analyzed by MaxQuant, 4 were following phosphopeptide enrichment (and therefore searched allowing phosphorylation as a variable modification). Eleven were either flow-throughs from enrichments or unenriched controls (therefore searched without allowing phosphorylation). Three experiments (13 raw files) employed Lys6, Arg10 labels, while one experiment employed only Lys6 label (2 raw files). All 15 files were combined in the 'Identify' step. An experimental design template was used to mark raw files as being from experiment 1, 2, 3, or 4 and also to indicate that the labeling in experiment 3 was inverted. Identifications were filtered using a peptide FDR of 0.01 and a protein FDR of 1.00 (no filtering at the protein level). Supplementary Table S1 ([Supporting Information](#si1){ref-type="notes"}) was created from the evidence.txt output for all four experiments, by sorting according to phospho (Y) site ID. Supplementary Table S2 ([Supporting Information](#si1){ref-type="notes"}) was created from the evidence.txt output for all dual labeled experiments, by sorting according to phospho (Y) site ID and SILAC ratio. Reverse hits and contaminants are not shown. All ratios obtained from MaxQuant were adjusted using a correction factor to allow for mixing error. This correction factor was calculated by combining all unenriched pre-IP control samples and normalizing peptide ratios so that the median of their logarithms is zero. In order to calculate the probability cut-offs (*p* = 0.05), the value for 2 × the standard deviation of the control ratio logarithms was calculated. Ratios were deemed significantly changed if they were \<0.616 or \>1.624. The correction factor was then applied to the enriched samples, and the means of the corrected ratio logarithms for each peptide were calculated. Variability (%) was calculated using the standard deviation of the natural logarithms of the SILAC ratios, multiplied by 100.

### Myc-Dok1 IP Plus/Minus Src Drug (SILAC) {#sec5.1.2}

Two separate experiments were carried out, resulting in 41 raw files. These were analyzed by MaxQuant, 3 were following phosphopeptide enrichment (and therefore searched allowing phosphorylation as a variable modification). Thiry-six were either gel-slices with no TiO~2~ enrichment or flow-throughs from enrichments, and two were pre-IP control samples (therefore searched without allowing phosphorylation). Both experiments employed Lys6, Arg10 labels. All 41 files were combined in the 'Identify' step. To obtain the phosphorylation-specific output columns, the phosphorylated samples were selected to be at the top of the list of files for 'Identify' to process. Identifications were filtered using a peptide FDR of 0.01 and a protein FDR of 0.01. An experimental design template was used to mark raw files as being from experiment 1 or 2. Supplementary Table S3 ([Supporting Information](#si1){ref-type="notes"}) was created from the proteingroups.txt output, by sorting according to normalized SILAC Ratio. Reverse hits and contaminants are not shown. For the enriched Dok1 gel slices, a correction factor was applied to each peptide ratio, calculated from nonenriched pre-IP control samples as described above. Ratios were deemed significantly changed if they were \<0.612 or \>1.635.

### Myc-Dok1 IP versus Untransfected (SILAC) {#sec5.1.3}

Two separate experiments were carried out, resulting in 34 raw files. These were analyzed by MaxQuant, 2 were following phosphopeptide enrichment (and therefore searched allowing phosphorylation as a variable modification). Thirty-two were either gel-slices with no TiO~2~ enrichment or flow-throughs from enrichments (therefore searched without allowing phosphorylation). Both experiments employed Lys6, Arg10 labels. All 34 files were combined in the 'Identify' step. In order to obtain the phosphorylation-specific output columns, the phosphorylated samples were selected to be at the top of the list of files for 'Identify'. Identifications were filtered using a peptide FDR of 0.01 and a protein FDR of 0.01. An experimental design template was used to mark raw files as being from experiment 1 or 2. Supplementary Table S4 ([Supporting Information](#si1){ref-type="notes"}) was created from the proteingroups.txt output, by sorting according to normalized SILAC Ratio. Reverse hits and contaminants are not shown.
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Supplementary Table S1, identification of phosphotyrosine peptides from SILAC ± SU6656. Supplementary Table S2, quantitation of phosphotyrosine peptides from SILAC ± SU6656. Supplementary Table S3, proteins identified in the myc-Dok1 vs untransfected SILAC experiment. Supplementary Table S4, proteins identified in the myc-Dok1 ± SU6656 SILAC experiment. Supplementary Figure S1, Overlap of phosphotyrosine peptide identification in four SILAC repeat experiments. Supplementary Figure S2, Overlap of phosphotyrosine peptide identification in three SILAC repeat experiments. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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